Literature DB >> 14501443

Lipopolysaccharide concentration and bone resorption in cholesteatoma.

F A W Peek1, M A Huisman, R J Berckmans, A Sturk, J Van Loon, J J Grote.   

Abstract

HYPOTHESIS: There is a relationship between the local lipopolysaccharide (LPS) concentration in cholesteatoma and local bone resorption in chronic otitis media (COM) with cholesteatoma.
BACKGROUND: During the past decade, it has become known that the recruitment of osteoclasts is the main causative factor that induces bone destruction in COM with cholesteatoma. Cellular inflammation factors like cytokines may trigger the osteoclast. Sequel to this, LPS is able to up-regulate cytokines. This makes it of interest to study whether the local LPS concentration is related to bone resorption in cholesteatoma.
MATERIALS AND METHODS: Twenty-four cholesteatoma samples and control tissue from COM patients without cholesteatoma were collected. During surgery, the degree of bone resorption was established and classified. Retrospectively, the authors checked whether patients had chronic purulent otorrhea. LPS concentration of the tissue samples was measured by the limulus amebocyte lysate test. The one-way analysis of variance test was used to determine the relation between LPS concentration, otorrhea, and local bone resorption.
RESULTS: A significantly higher concentration of LPS was measured in samples from patients with cholesteatoma with bone resorption and otorrhea compared with cholesteatoma without bone resorption and control tissue. There were no significant differences between the LPS levels of the different groups of patients with bone resorption.
CONCLUSION: It is suggested that LPS is one of the first factors in the cascade of bone resorption in COM with cholesteatoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501443     DOI: 10.1097/00129492-200309000-00002

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  17 in total

1.  Osteoclasts Modulate Bone Erosion in Cholesteatoma via RANKL Signaling.

Authors:  Ryusuke Imai; Takashi Sato; Yoriko Iwamoto; Yukiko Hanada; Mika Terao; Yumi Ohta; Yasuhiro Osaki; Takao Imai; Tetsuo Morihana; Suzuyo Okazaki; Kazuo Oshima; Daisuke Okuzaki; Ichiro Katayama; Hidenori Inohara
Journal:  J Assoc Res Otolaryngol       Date:  2019-06-28

2.  Lipopolysaccharide-induced osteoclastogenesis from mononuclear precursors: a mechanism for osteolysis in chronic otitis.

Authors:  Robert Nason; Jae Y Jung; Richard A Chole
Journal:  J Assoc Res Otolaryngol       Date:  2009-01-15

3.  Toll-like receptors 2, 3 and 4 (TLR-2, TLR-3 and TLR-4) are expressed in the microenvironment of human acquired cholesteatoma.

Authors:  Mirosław Szczepański; Witold Szyfter; Renata Jenek; Maciej Wróbel; Iwona Mozer Lisewska; Jan Zeromski
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-03-15       Impact factor: 2.503

4.  Myeloperoxydase activity in the pathogenesis of cholesteatoma.

Authors:  Ozlem Celebi; Mustafa Paksoy; Sedat Aydin; Arif Sanlı; Omer Taşdemir; Aylin Ege Gül
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2010-06-04

5.  Cholesteatoma growth and proliferation: posttranscriptional regulation by microRNA-21.

Authors:  David R Friedland; Rebecca Eernisse; Christy Erbe; Nidhi Gupta; Joseph A Cioffi
Journal:  Otol Neurotol       Date:  2009-10       Impact factor: 2.311

6.  FleQ, a Transcriptional Activator, Is Required for Biofilm Formation In Vitro But Does Not Alter Virulence in a Cholesteatomas Model.

Authors:  Wee Tin K Kao; Patricia M Gagnon; Joseph P Vogel; Richard A Chole
Journal:  Otol Neurotol       Date:  2016-08       Impact factor: 2.311

7.  The evaluation of oxidative stress in the serum and tissue specimens of patients with chronic otitis media.

Authors:  Mehmet Fatih Garça; Mahfuz Turan; Barış Avşar; Ferhat Kalkan; Halit Demir; Ahmet Kozan; Nazım Bozan
Journal:  Clin Exp Otorhinolaryngol       Date:  2015-05-13       Impact factor: 3.372

8.  Cytokeratin 13, Cytokeratin 17, and Ki-67 Expression in Human Acquired Cholesteatoma and Their Correlation With Its Destructive Capacity.

Authors:  Mahmood A Hamed; Seiichi Nakata; Kazuya Shiogama; Kenji Suzuki; Ramadan H Sayed; Yoichi Nishimura; Noboru Iwata; Kouhei Sakurai; Badawy S Badawy; Ken-Ichi Inada; Hayato Tsuge; Yutaka Tsutsumi
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-01-12       Impact factor: 3.372

9.  Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study.

Authors:  Ravi N Samy; Brian R Earl; Noga Lipschitz; Ivy Schweinzger; Mark Currier; Timothy Cripe
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-10-15

Review 10.  Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future Prospectives.

Authors:  Mahmood A Hamed; Seiichi Nakata; Ramadan H Sayed; Hiromi Ueda; Badawy S Badawy; Yoichi Nishimura; Takuro Kojima; Noboru Iwata; Ahmed R Ahmed; Khalid Dahy; Naoki Kondo; Kenji Suzuki
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-07-21       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.